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Allergen-induced airway infl  ammation in asthma 
is characterized by eosinophil and CD4+ and 
CD8+ T cell infi  ltration of the airways and ac-
companied by airway structural changes (i.e., 
airway remodeling), including goblet cell meta-
plasia, increased smooth muscle mass, and sub-
epithelial fi  brosis from excessive deposition of 
extracellular matrix components such as colla-
gen and laminin (for review see references 1, 2). 
Leukotrienes and prostaglandins are, respec-
tively, 5-lipoxygenase and cyclooxygenase me-
tabolites of arachidonic acid (i.e., eicosanoids) 
that are important in the pathogenesis of asthma. 
Release of 5-lipoxygenase products leukotriene 
B4 (LTB4), the cysteinyl leukotrienes (cysLTs) 
C4, D4, and E4, and cyclooxygenase products 
prostaglandin D2 (PGD2) and thromboxane A2 
from infl  amed airways leads to airway hyperre-
sponsiveness and airfl  ow obstruction with mu-
cus glyco proteins. Evidence from animal models 
and patients with asthma suggest that these 
eicosanoids are key molecules that promote air-
way infl  ammation as potent chemoattractants 
for eosinophils, T cells, and other infl  ammatory 
cells; cause plasma extravasation and edema; 
modulate airway smooth muscle cell function; 
and induce release of extracellular matrix com-
ponents (3–5).
The availability of free arachidonate in cells 
and, thus, the biosynthesis of leukotrienes and 
other eicosanoids, including prostaglandins, is 
tightly controlled by the regulated action of 
phospholipase A2s (PLA2s) that release this fatty 
acid by hydrolysis of the sn-2 ester of glycero-
phospholipids present as major components of 
cell membranes. Mammalian cells contain mul-
tiple types of PLA2s (6), but it is generally 
  accepted that cytosolic group IVA PLA2-α 
(cPLA2-α; also known as group IVA PLA2; 
PLA2G4A) plays a pivotal role in agonist-
  mediated arachidonate release for the biosynthe-
sis of the eicosanoids. This is based on studies 
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Arachidonic acid metabolites, the eicosanoids, are key mediators of allergen-induced airway 
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cytosolic PLA2-𝗂. 10 secreted PLA2s (sPLA2s) have also been identifi  ed, but their function 
in eicosanoid generation is poorly understood. We investigated the role of group X sPLA2 
(sPLA2-X), the sPLA2 with the highest in vitro cellular phospholipolysis activity, in acute 
and chronic mouse asthma models in vivo. The lungs of sPLA2-X−/− mice, compared with 
those of sPLA2-X+/+ littermates, had signifi  cant reduction in ovalbumin-induced infi  ltration 
by CD4+ and CD8+ T cells and eosinophils, goblet cell metaplasia, smooth muscle cell layer 
thickening, subepithelial fi  brosis, and levels of T helper type 2 cell cytokines and eico-
sanoids. These data direct attention to sPLA2-X as a novel therapeutic target for asthma.
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with cPLA2-α   inhibitors (7–10) and cPLA2-α–defi  cient mice 
(11–13). The mammalian genome also encodes 10 secreted 
PLA2s (sPLA2s). The role of these enzymes in eicosanoid 
  biosynthesis is much less clear. Disruption of the group V 
sPLA2 gene (PLA2G5) in mice leads to  50% reduction 
in the amount of LTC4 and PGE2 production in zymosan-
stimulated peritoneal macrophages (14). Group IIA, V, and 
X sPLA2s have been shown to coordinate with cPLA2-α to 
augment arachidonate release from cultured cells (15–20), but 
the mechanism for this coordinate action between cPLA2-α 
and sPLA2 is not known.
A systematic investigation of the interfacial kinetic and 
binding properties of the full set of mouse and human 
sPLA2s shows that the group X sPLA2 (sPLA2-X; PLA2G10) 
stands out as having the highest phospholipolysis activity 
when added to cultured cells (21, 22). Based on these fi  nd-
ings and the fact that sPLA2-X is expressed in human (23, 24) 
and mouse lungs (this study), we investigated the possible 
role of sPLA2-X in a mouse asthma model by generating a 
sPLA2-X–defi   cient mouse for studies of allergen-induced 
airway infl  ammation and remodeling. In this initial study, 
we explored an animal disease model rather than experi-
ments with single cell types in vitro, because sPLA2-X is a 
secreted enzyme and can potently act extracellularly on 
many, if not all, mammalian cell types to liberate arachidonic 
acid. Therefore, studies with cultured mammalian cells 
  cannot shed suffi   cient light on the behavior of sPLA2-X in 
tissues. This is a diff  erent situation than with cPLA2-α that 
acts in the cytoplasm.
RESULTS
Generation and characterization of the sPLA2-X−/− mouse
Mutation of the mouse sPLA2-X gene was accomplished by 
retroviral-mediated insertion of an exon-trapping cassette 
(see Materials and methods). DNA sequence analysis revealed 
that the trapping cassette is located in the intron between 
exons 3 and 4 of the sPLA2-X gene. Real-time (RT)–PCR 
analysis using primers hybridizing to exons 2 and 4 and 
cDNA made from mouse testis, colon, and stomach revealed 
 1,000-fold reduction in sPLA2-X mRNA levels in the 
sPLA2-X−/− mouse versus the wild-type littermate. We also 
looked for sPLA2-X protein in stomach extracts using a sensi-
tive time-resolved fl  uorescence immunoassay (25). When 
24  μg of stomach lysate protein was analyzed from a 
sPLA2-X+/+ mouse, 0.2 ng sPLA2-X protein was detected, 
whereas no sPLA2-X protein was detected when 34 μg of 
lysate protein from a sPLA2-X−/− mouse was used.
Allergen-induced airway infl  ammation and expression 
of sPLA2-X
Important insights into the mechanisms of chronic infl  amma-
tion and remodeling in asthma have come from animal mod-
els that reproduce key morphologic and physiologic features 
of human asthma. To study the in vivo eff  ects of sPLA2 defi  -
ciency on the asthma phenotype, we used OVA as a model 
allergen to induce allergen-specific pulmonary disease in 
wild-type and sPLA2-X−/− mice. In the acute asthma proto-
col (3), OVA-sensitized mice challenged with four doses of 
OVA display, by day 29, a disease strikingly similar to allergen-
induced human asthma, including (a) circulating levels of 
allergen-specifi  c IgE; (b) a marked infl  ux of eosinophils and 
T cells into the airways; (c) increased levels of mucus glyco-
proteins, Th2 cell cytokines (IL-4, IL-5, and IL-13), and leu-
kotrienes and other eicosanoids in bronchoalveolar lavage 
(BAL) fl  uid; and (d) pulmonary hyperreactivity to methacho-
line compared with saline-treated control mice. When the 
intranasal (i.n.) OVA challenges are continued periodically 
in the chronic asthma protocol (4, 26), by day 76 the mice 
have striking features of airway remodeling, including (a) 
goblet cell metaplasia, (b) increased smooth muscle cell layer 
Figure 1.  Absent sPLA2-X expression in lungs of sPLA2-X−/− mice. 
Lung tissue was obtained on day 29 (acute asthma model) from sPLA2-X+/+ 
and sPLA2-X−/− mice treated with either OVA or saline and examined 
by immunocytochemistry for sPLA2-X expression. Arrows indicate per-
oxidase-positive cells in the airways (AW) expressing sPLA2-X. Additional 
airway sections of OVA-treated sPLA2-X+/+ mice are shown in Fig. S1. 
Absent sPLA2-X expression in the splenic tissue of sPLA2-X−/− mice is 
shown in Fig. S2. Bars, 50 μm.JEM VOL. 204, April 16, 2007  867
ARTICLE
mass, and (c) extensive subepithelial collagen deposition and 
airway wall thickening.
sPLA2-X expression in the lungs and the spleen of 
sPLA2-X−/− and wild-type mice in the acute asthma model was 
examined by immunocytochemistry. sPLA2-X was expressed in 
the airway epithelium in the lungs in saline-treated wild-type 
mice but not in sPLA2-X−/− mice (Fig. 1). After OVA sensi-
tization and challenge, sPLA2-X expression greatly increased 
in the columnar cells lining the airways of wild-type mice 
but remained undetected in sPLA2-X−/− mice (Fig. 1 and 
Fig. S1, available at http://www.jem.org/cgi/content/full/
jem.20070029/DC1). Confocal immunofl  uorescence micro-
scopy demonstrated colocalization of sPLA2-X with airway 
epithelial cells expressing mucin 5AC glycoprotein (Fig. 2). 
Macrophages contributed to sPLA2-X expression in the airways, 
because alveolar macrophages, isolated from BAL fl  uid cells 
of OVA-treated wild-type mice (but not sPLA2-X−/− mice), 
exhibited strong reactivity for sPLA2-X by immunocyto-
chemistry (Fig. 3). Splenic mononuclear cells also expressed 
sPLA2-X in sPLA2-X+/+ mice but not in sPLA-X−/− mice 
(Fig. S2). No staining reaction for sPLA2-X was observed 
when immunocytochemistry was performed with preim-
mune serum (Fig. S2).
Effect of sPLA2-X defi  ciency on allergen-induced 
recruitment of infl  ammatory cells into the lungs 
and hyperresponsiveness
On day 29, 24 h after the fi  nal i.n. OVA challenge in animals 
from each experimental group (i.e., acute asthma model), the 
eff  ect of sPLA2-X defi  ciency on allergen-induced airway 
infl   ammation and hyperreactivity was determined. OVA-
treated sPLA2-X+/+ mice had a sixfold increase in total cells 
recovered in BAL fl  uid compared with the saline group con-
trol (Fig. 4 a);  50% of the BAL fl  uid cells were eosinophils 
in the OVA-treated sPLA2-X+/+ mice. The total number of 
infl  ammatory cells and eosinophils in the BAL fl  uid of OVA-
treated sPLA2-X−/− mice was signifi  cantly reduced compared 
with wild-type controls (Fig. 4 a). By light microscopy and 
morphometry, an infl   ux of eosinophils and mononuclear 
cells into the lungs around the airways and blood vessels, air-
way goblet cell metaplasia/mucus hypersecretion, and inter-
stitial edema were observed in OVA-treated sPLA2-X+/+ 
mice compared with saline controls (Fig. 4, b and c; and 
Fig. S3, available at http://www.jem.org/cgi/content/full/
jem.20070029/DC1). This increased infi  ltration of total in-
fl  ammatory cells and eosinophils, goblet cell metaplasia/
mucus hypersecretion, and edema of the airway interstitium were 
markedly decreased in OVA-treated sPLA2-X−/− mice com-
pared with sPLA2-X+/+ mice (Fig. 4, b and c; and Fig. S3). 
Using invasive plethysmography to determine lung resistance 
(RL), airway hyperreactivity to aerosolized methacholine was 
signifi  cantly increased in the OVA-treated wild-type mice 
compared with saline controls (Fig. 4 d). In contrast, pulmo-
nary responses in the sPLA2-X−/− mice were not signifi  cantly 
diff   erent between the OVA and saline treatment groups 
(Fig. 4 d). In vivo airway responsiveness to aerosolized metha-
choline was also determined on day 29 in conscious, freely 
moving, spontaneously breathing mice using noninvasive 
whole-body plethysmography, and the same trends for Penh 
Figure 2.  Colocalization of sPLA2-X with airway epithelial cells 
expressing mucin 5AC glycoprotein in OVA-treated wild-type mice. 
Red fl  uorophore (Alexa Fluor 594) localization of sPLA2-X (left), green 
fl  uorophore (Alexa Fluor 488) localization of mucin 5AC (middle), and 
colocalization of sPLA2-X with mucin 5AC–positive airway epithelial cells 
(right). Bar, 20 μm.
Figure 3.  sPLA2-X expression in alveolar macrophages of wild-type 
mice. Alveolar macrophages were isolated on day 29 from sPLA2-X+/+ 
and sPLA2-X−/− mice treated with either OVA or saline and examined by 
immunocytochemistry for sPLA2-X expression. Bar, 50 μm.868  GROUP X PHOSPHOLIPASE A2 AND AIRWAY INFLAMMATION | Henderson et al.
Figure 4.  Impaired allergen-induced airway infl  ammation and 
hyperreactivity in sPLA2-X−/− mice. (a) BAL fl  uid was obtained on day 29 
from saline-treated (n = 5) and OVA-treated (n = 9) sPLA2-X+/+ mice 
(+/+) and saline-treated (n = 7) and OVA-treated (n = 8) sPLA2-X−/− 
mice (−/−), and the number of total cells and percentage and number of 
eosinophils were determined. (b) Lung sections of saline- and OVA-treated 
sPLA2-X+/+ and sPLA2-X−/− mice were stained with hematoxylin and eo-
sin. Arrows indicate infl  ammatory cells. AW, airways; BV, blood vessels. 
Bars, 100 μm. (c) The intensity of the total infl  ammatory cell infi  ltrate 
(0–4+ scale), the number of eosinophils per unit area (2,200 μm2), and 
airway edema (0–4+ scale) in the lungs on day 29 were determined by 
morphometric analysis. (d) Allergen-induced airway hyperresponsiveness 
was assessed by invasive plethysmography on day 29 in wild-type (+/+) 
and sPLA2-X−/− (−/−) mice as the degree of bronchoconstriction to 
aerosolized methacholine (0, 3.125, 6.25, 12.5, 25, and 50 mg/ml). RL was 
calculated as described in Materials and methods and is shown as the 
percentage of baseline response to aerosolized normal saline. *, P < 0.05 
versus saline. Data in a, c, and d represent the mean ± SEM.JEM VOL. 204, April 16, 2007  869
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values were observed as for the invasive RL measurements 
(unpublished data).
Effect of sPLA2-X defi  ciency on allergen-induced 
airway remodeling
Wild-type mice challenged with OVA periodically over a 
75-d period (i.e., chronic asthma model) had persistent 
airway infi  ltration by eosinophils and edema (Fig. 5 a; and 
Fig. S4 and Fig. S5, available at http://www.jem.org/cgi/
content/full/jem.20070029/DC1), goblet cell metaplasia 
and mucus hypersecretion on day 76 (Fig. 5, a and b), and 
increased airway smooth muscle mass and collagen deposi-
tion (Fig. 6, a and b) compared with saline controls. These 
features of allergen-induced airway remodeling were signifi  -
cantly reduced in sPLA2-X−/− mice (Fig. 5, a and b; and 
Fig. 6, a and b).
Effect of sPLA2-X defi  ciency on Th2 responses
A molecular hallmark of asthma is Th2 cytokine expression. 
We examined the eff  ect of sPLA2-X defi  ciency on Th2 cell–
driven OVA-specifi  c IgE levels, traffi   cking of T cells to the 
lungs, and pulmonary Th2 versus Th1 cytokine expression 
in both the acute and chronic mouse asthma models. Circu-
lating levels of allergen-specifi  c IgE in blood were reduced 
on day 29 in sPLA2-X−/− mice compared with wild-type 
controls after OVA treatment (Fig. 7 a). A substantial in-
crease in the total number of T cells and also in the numbers 
of both CD4+ and CD8+ cells was seen in the BAL fl  uid of 
wild-type mice after OVA treatment on day 29 (Fig. 7 b). In 
contrast, negligible traffi   cking of T cells to the BAL fl  uid 
was observed in allergen-challenged sPLA2-X−/− mice (Fig. 
7 b). By RT-PCR, gene expression of the Th2 cytokines 
IL-4, IL-5, and IL-13 was markedly increased in whole-lung 
tissue of OVA-sensitized/challenged sPLA2-X+/+ mice 
compared with saline-treated controls on day 76 (Fig. 7 c). 
In OVA-treated sPLA2-X−/− mice compared with wild-
type controls, gene expression of IL-4, IL-5, and IL-13 was 
signifi  cantly reduced (Fig. 7 c). No signifi  cant change in 
gene expression of the Th1 cytokines IL-2 and IFN-γ, the 
lymphocyte-activating factor IL-1β, or the Th1-inducing 
cytokine IL-12 was seen in either wild-type or sPLA2-X−/− 
mice after OVA treatment compared with saline controls 
(Fig. 7 c). Signifi  cant levels of IL-4, IL-5, and IL-13 proteins 
were found in the BAL fl  uid of OVA-treated sPLA2-X+/+ 
mice compared with the saline control group on day 76 (Fig. 
7 d). In the BAL fl  uid of OVA-treated sPLA2-X−/− mice, 
IL-4 was not detected, and IL-5 and IL-13 levels were signif-
icantly reduced compared with wild-type controls (Fig. 7 d). 
IL-1β, IL-2, IL-12 (p70), and IFN-γ were not detected in the 
BAL fl  uid of wild-type and sPLA2-X−/− mice after either 
  saline or OVA treatment. Similar reductions in the pulmonary 
Th2 cytokine responses were observed in sPLA2-X−/− compared 
Figure 5.  sPLA2-X defi  ciency decreases allergen-induced goblet 
cell metaplasia. (a) Lung tissue was obtained on day 76 (chronic asthma 
model) from sPLA2-X+/+ and sPLA2-X−/− mice treated with either saline or 
OVA and stained with alcian blue/PAS. Arrowheads indicate goblet cells, 
and arrows indicate infl  ammatory cells. AW, airways; BV, blood vessels. 
Bars, 100 μm. (b) The occlusion of airway diameter by mucus (0–4+ scale) 
and the percentage of total airway epithelial cells positive for mucus 
glycoproteins by alcian blue/PAS staining in the lungs were deter-
mined by morphometric analysis (n = 4 for each group). Impaired 
allergen-induced airway goblet cell metaplasia and mucus hypersecretion 
in sPLA2-X−/− mice on day 29 in an acute asthma model are shown in 
Fig. S3. Data represent the mean ± SEM.870  GROUP X PHOSPHOLIPASE A2 AND AIRWAY INFLAMMATION | Henderson et al.
with wild-type mice in the acute asthma model (unpub-
lished data).
To examine the eff  ect of sPLA2-X defi  ciency on systemic 
CD4+ T cell–mediated production of Th2 cytokines in re-
sponse to antigenic challenge, we used fl  ow cytometric anal-
ysis to examine production of IL-4, IL-5, and IL-10, as well 
as the proinfl  ammatory cytokines IFN-γ and TNF-α, upon 
overnight in vitro stimulation of splenic CD4+ T cells from 
OVA-immunized and unimmunized mutant and wild-type 
mice in the presence of OVA. Comparable antigen-specifi  c 
production of IL-5 (Fig. 8 a) and IL-10 (Fig. 8 a) was de-
tected in both mutant and wild-type T cells, as indicated 
by  2–2.5-fold increase in the percentage of cytokine-
producing CD4+ T cells in the presence versus absence of 
OVA. In contrast to IL-5 and IL-10, antigen-specifi  c pro-
duction of IL-4, IFN-γ, and TNF-α was not detected using 
intracellular cytokine staining, suggesting that the frequency 
of OVA-specifi  c CD4+ T cells producing these cytokines 
was below the detection level (unpublished data). Therefore, 
we used a single-cell immunospot assay (ELISPOT) to mea-
sure their OVA-stimulated production of IL-4 and IFN-γ. In 
agreement with fl  ow cytometric analyses of IL-5 and IL-10 
production, we found no diff  erence in their ability to pro-
duce IL-4 (Fig. 8 c) and IFN-γ (Fig. 8 d). Further, there was 
a comparable ability to produce IL-4 by splenic CD4+ T cells 
from sPLA2-X−/− mice and wild-type controls in response to 
anti-CD3/anti-CD28 stimulation (Fig. 8 e). Thus, sPLA2-X 
defi  ciency does not result in a general repression of Th2 or 
Th1 cytokine production.
Effect of sPLA2-X defi  ciency on eicosanoid release
To assess the eff  ect of sPLA2-X defi  ciency on arachidonic 
acid release, we used an acute asthma model to measure the 
levels of eicosanoids that are derived from this fatty acid, spe-
cifi  cally via the cyclooxygenase pathway leading to PGD2 
and PGE2 and via the 5-lipoxygenase pathway leading to 
LTB4 and cysLTs C4, D4, and E4 (i.e., total cysLTs). Because 
of its chemical instability (27), PGD2 was converted to a 
  stable methoxime (MOX) derivative to prevent its further 
chemical degradation, and PGD2-MOX was assayed to de-
termine PGD2 levels. Because PGE2 is rapidly and exten-
sively metabolized in vivo (28), both native PGE2 and its 
13,14-dihydro-15-keto metabolite were assayed to deter-
mine the total PGE2 levels produced. In an acute asthma 
Figure 6.  sPLA2-X defi  ciency reduces allergen-induced increased 
smooth muscle cell layer mass and subepithelial fi  brosis. (a) Lung 
tissue was obtained on day 76 from sPLA2-X+/+ and sPLA2-X−/− mice 
treated with either saline or OVA and stained with Masson’s trichrome stain. 
Arrows indicate collagen and arrowheads indicate mucus. AW, airways. 
Bars, 100 μm. (b) Airway smooth muscle cell layer mass and sub-
epithelial collagen deposition were determined by morphometry (0–4+ 
scale). Impaired allergen-induced BAL fl  uid eosinophilia and airway tissue 
infl  ammation on day 76 in sPLA2-X−/− mice in a chronic asthma model are 
shown in Fig. S4 and Fig. S5, respectively. Data represent the mean ± SEM.JEM VOL. 204, April 16, 2007  871
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model, PGD2 (Fig. 9 a), PGE2 (Fig. 9 b), LTB4 (Fig. 9 c), and 
cysLT (Fig. 9 d) levels were each signifi  cantly increased in the 
BAL fl  uid of sPLA2-X+/+ mice after OVA treatment com-
pared with saline controls with cysLTs>>PGE2>LTB4>PGD2. 
The 13,14-dihydro-15-keto-PGE2 metabolite represented 
91% of total PGE2 levels in the OVA-treated wild-type mice. 
As determined by liquid chromatography–electrospray 
tandem mass spectrometry, the fractional distribution of 
LTC4, LTD4, and LTE4 was similar in the BAL fl  uid  of 
OVA- and saline-treated wild-type mice, with LTE4 the pre-
dominant cysLT recovered (i.e., the respective fractional dis-
tributions of LTC4:LTD4:LTE4 in OVA- and saline-treated 
sPLA2-X+/+ mice were 0.11:0.26:0.63 and 0.10:0.25:0.65, 
respectively). The levels of PGD2, PGE2, LTB4, and cysLTs 
in the BAL fl  uid of allergen-challenged sPLA2-X−/− mice 
were not signifi  cantly diff  erent than those of saline-controls 
(Fig. 9, a–d). The fractional distribution of LTC4, LTD4, and 
LTE4 in the BAL fl  uid of OVA- and saline-treated sPLA2-X−/− 
mice was the same as that observed for wild-type controls 
(0.11:0.26:0.63 for OVA-treated sPLA2-X−/− mice and 
0.10:0.25:0.65 for saline-treated sPLA2-X−/− mice). On day 76 
compared with saline controls (chronic model), both cycloox-
ygenase (i.e., PGE2) and 5-lipoxygenase (i.e., cysLTs) products 
of arachidonic acid were substantially increased in the BAL 
fl  uid of wild-type but not sPLA2-X−/− mice after OVA treat-
ment (unpublished data).
DISCUSSION
Our results suggest that sPLA2-X plays a critical role in the 
pathogenesis of the asthma phenotype. The major fi  ndings 
of this study are that defi  ciency of sPLA2-X in mice sub-
stantially reduces allergen-induced (a) airway eosinophil 
and CD4+ and CD8+ T cell traffi   cking, mucus hypersecre-
tion, and hyperresponsiveness to methacholine in an acute 
model of asthma; (b) airway remodeling (i.e., goblet cell meta-
plasia, smooth muscle cell layer thickening, and subepi-
thelial fi  brosis in the lungs) in a chronic asthma model; and 
(c) Th2 cytokine and eicosanoid levels in these models of 
human asthma.
Our data suggest that sPLA2-X plays a role in eicosanoid 
generation and that the reduction in eicosanoid generation 
seen in the sPLA2-X−/− mice leads to a decrease in Th2 re-
sponses. The Th2 cell subset of CD4+ T cells has been recog-
nized as pivotal in the development of this allergen-induced 
airway eosinophilic infi  ltration, mucus hypersecretion, fi  bro-
sis, and hyperreactivity through the secretion of IL-4, IL-5, 
and IL-13 cytokines. More recently, CD8+ T cells have been 
demonstrated to substantially contribute to these allergen-
induced responses by their traffi   cking to the lungs and local 
generation of IL-13 (29). We found that sPLA2-X defi  ciency 
Figure 7.  Impaired Th2 cytokine responses in sPLA2-X−/− mice. 
(a) OVA-specifi  c IgE levels were determined in plasma obtained on day 29 
from saline- and OVA-treated mGX+/+ (+/+) and sPLA2-X−/− (−/−) 
mice. (b) The number of CD3+, CD4+, and CD8+ T cells in the BAL fl  uid on 
day 29 was determined by fl  ow cytometry. Low cell levels (×103) not 
shown on the graph are as follows: saline-treated wild-type mice (CD3+, 
0.111 ± 0.001; CD4+, 0.083 ± 0.002; and CD8+, 0.028 ± 0.002 [reference 1]); 
saline-treated sPLA2-X−/− mice (CD3+, 0.103 ± 0.002; CD4+, 0.079 ± 
0.001; and CD8+ 0.028 ± 0.003 [(reference 2]); and OVA-treated sPLA2-X−/− 
mice (CD3+, 0.264 ± 0.051; CD4+, 0.196 ± 0.025; and CD8+, 0.065 ± 0.005 
[reference 3]). *, P < 0.05 for both saline versus OVA in +/+ mice 
and OVA in +/+ mice versus OVA in −/− mice. (c) IL-1β, IL-2, IL-4, IL-5, 
IL-12α, IL-12β, IL-13, and IFN-γ mRNAs were determined by RT-PCR in 
whole-lung tissue from sPLA2-X+/+ and sPLA2-X−/− mice on day 76. 
(d) IL-4, IL-5, and IL-13 protein levels (pg/ml) were determined in the BAL 
fl  uid obtained on day 76 in saline- and OVA-treated sPLA2-X+/+ (+/+) 
and sPLA2-X−/− mice (−/−). *, P < 0.05 for both saline versus OVA in 
+/+ mice and OVA in +/+ mice versus OVA in −/− mice. Data repre-
sent the mean ± SEM.872  GROUP X PHOSPHOLIPASE A2 AND AIRWAY INFLAMMATION | Henderson et al.
resulted in a marked decrease in movement of both CD4+ 
and CD8+ T cells to the airway lumen that was associated 
with diminished pulmonary Th2 cytokine gene and protein 
expression. Splenic T cells from the sPLA2-X−/− mice showed 
normal induction of Th2 and Th1 cytokines with ex vivo 
stimulation. Thus, the marked impairment in the ability of 
the mutant mice to recruit allergen-specifi  c T cells to the 
lungs likely accounts for the observed diminution in pulmo-
nary Th2 cytokine production and infl  ammation.  Among 
other key eff  ects on the asthma phenotype, IL-13 induces se-
cretion of mucin 5AC glycoprotein, diff  erentiation of ciliated 
epithelial cells into goblet cells (30), and release of TGFβ, 
leading to fi  brosis (31) in the airways of mice after allergen 
challenge. IL-4, in the absence of other Th2 cytokines, can 
also induce typical Th2 responses, including airway goblet 
cell metaplasia, in a mouse asthma model (32). IL-5 promotes 
growth and maturation of eosinophil precursors and stimu-
lates the chemotaxis of mature eosinophils, prolonging their 
survival in allergic infl  ammatory tissue sites by inhibition of 
apoptosis (2). In both wild-type and sPLA2-defi  cient mice, 
Th1 cytokines remained low after OVA stimulation.
We found that in sPLA2-X–defi   cient mice, there is a 
  reduction in elevated levels of eicosanoids found in OVA-
treated wild-type mice, and this likely leads to an amelioration 
of the asthma phenotype. In mouse models of asthma, spe-
cifi   c inhibitors of 5-lipoxygenase, or leukotriene receptor 
antagonists, considerably reduce indices of allergic airway in-
fl  ammation, including Th2 cytokine levels (3, 4). The cysLT1 
receptor antagonist montelukast inhibits Th2 cytokine gene 
and protein expression in the lungs of sensitized mice chroni-
cally challenged with OVA (4). Further, established and per-
sistent airway eosinophilia, goblet cell metaplasia, increased 
airway smooth muscle mass, and subepithelial fi  brosis in a 
mouse model of allergen-induced airway remodeling are re-
versible by cysLT1 receptor blockade (26). The cysLTs pro-
mote growth of eosinophil progenitors from the blood and 
bone marrow of atopic individuals (33), stimulate eosinophil 
chemotaxis, and increase their survival in tissue sites of al-
lergic infl  ammation. Bronchial smooth muscle cells, with 
increased cysLT1 receptor expression after TGFβ and IL-13 
treatment, proliferate in response to LTD4 (34). cysLTs also 
induce the release of mucus by airway goblet cells (3) and 
collagen by TGFβ-transformed lung myofi  broblasts  (35). 
In IL-13–induced airway infl  ammation and remodeling in 
mice, 5-lipoxygenase inhibitors, as well as cysLT1 and LTB4 
Figure 8.  sPLA2-X defi  ciency does not affect cytokine production 
in CD4+ T cells. For fl  ow cytrometric analysis of intracellular cytokines, 
splenocytes from saline- and OVA-treated sPLA2-X−/− and sPLA2-X+/+ 
mice were cultured with or without 200 μg/ml OVA in the presence of 
antigen-presenting cells and stained for surface CD4 and the cytokines 
IL-5 (a) and IL-10 (b). The percentage of cytokine-producing CD4+ cells 
from individual animals is shown. Horizontal bars represent the mean for 
three different age- and sex-matched animals. + represents cells acti-
vated in vitro with OVA, and − represents control cells incubated with 
PBS. For ELISPOT assay of IL-4 (c and e) and IFN-γ (d) production, spleno-
cytes from sPLA2-X+/+ mice treated with saline (+/+) or OVA (+/+) and 
sPLA2-X−/− mice treated with saline (−/−) or OVA (−/−) were incubated 
in the absence (untreated) or presence of either 5 ng/ml PMA/500 ng/ml 
ionomycin (PMA + ionomycin) or 500 μg/ml OVA (c and d), or CD4+ cells 
isolated from the total splenic cells were incubated in the absence (un-
treated) or presence of anti-CD3/anti-CD28 antibodies (e). Data represent 
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receptor antagonists, reduce eosinophil infi  ltration, mucus 
cell metaplasia, and collagen deposition in the airways, indi-
cating that both LTB4 and cysLTs C4, D4, and E4 substantially 
contribute to the eff  ects of IL-13 on the lung (5).
Recent studies have indicated an important role for LTB4 
and PGD2 in directing T cells to the airways in asthma. Using 
mice defi  cient in the LTB4 receptor BLT1, a requirement of 
the LTB4–BLT1 pathway, has been demonstrated as crucial 
for the early recruitment of CD4+ and CD8+ T cells to the 
airways after allergen challenge (36). The T cell–mediated 
allergen-induced airway hyperresponsiveness in this model is 
dependent on BLT1 and is associated with IL-13 production 
by the T cells (37, 38). Increased numbers of BLT1+ T cells 
are found in the airways of allergic individuals with asthma (39). 
Mice defi  cient in DP1, one of the receptors for PGD2, have 
decreased airway Th2 cytokines, eosinophil infi  ltration, and 
mucus hypersecretion compared with wild-type controls af-
ter allergen sensitization and challenge (40). PGD2 induces 
preferential generation of Th2 cytokines by its interaction 
with the chemoattractant receptor–like molecule expressed 
on Th2 cells (41).
 Over the past decade, it has generally been considered 
that cPLA2-α is the master regulator of arachidonate release 
from cellular phospholipids. Early reports showed that group 
IIA sPLA2 (PLA2G2A) rises to high levels in serum and syno-
vial fl  uid in patients suff  ering from infl  ammatory disorders, 
including acute pancreatitis and rheumatoid arthritis (42, 43), 
but there was no evidence showing that group IIA sPLA2 is 
directly responsible for the liberation of arachidonate from 
phospholipids for the biosynthesis of eicosanoids. More recent 
work has shown that sPLA2s can augment the action of 
cPLA2-α in cells to liberate arachidonate. Peritoneal macro-
phages from group V sPLA2-defi  cient mice produce  50% as 
much free arachidonate compared with wild-type cells after 
stimulation with zymosan, a fungal cell wall–derived agonist 
(14), yet there is essentially no arachidonate released in this 
system when macrophages from cPLA2-α–defi  cient mice are 
used (13). Earlier studies with antisense technology to knock 
down the level of group V sPLA2 also support a role for a 
joint action of group V sPLA2 and cPLA2-α in macrophages (16). 
Thus, cPLA2-α and group V sPLA2 work together by an 
unknown mechanism leading to maximal arachidonate 
release. Because both enzymes are PLA2s that can hydrolyze 
arachidonyl-containing phospholipids, it is not possible at 
this point to know which enzyme is directly responsible for 
most of the phospholipid sn-2 lipolysis leading to arachi-
donate release.
In rat gastric epithelial cells (RGM1) and in rat fi  broblasts 
(3Y1), cytokine-induced arachidonate release and PGE2 pro-
duction coincide with up-regulation and secretion of group 
IIA sPLA2 into the culture medium, and studies with cPLA2-α 
and sPLA2 inhibitors support a coordinate role for both 
enzymes in arachidonate release (15, 17). Coordinate action 
of cPLA2-α and sPLA2s has also been recently reported in 
transfected cells (18, 19). There are no reports showing that 
endogenous sPLA2-X is directly involved in arachidonic acid 
release from mammalian cells in culture. Nevertheless, we 
decided to explore the sPLA2-X−/− mouse in an animal 
model of asthma because of the high activity that this enzyme 
shows when added to mammalian cells in culture (21, 22). 
The results of the present study showing a clear role for 
sPLA2-X in mediating airway infl   ammation in a mouse 
model of allergic asthma are thus important and novel. Our 
study is the fi  rst to demonstrate an important role for an 
sPLA2 in an animal model of asthma. It remains to be seen if 
other mammalian sPLA2s play a role in airway infl  ammation 
and hyperreactivity.
Figure 9.  Impaired eicosanoid release in sPLA2-X−/− mice. (a) PGD2 
(PGD2-MOX), (b) PGE2 (PGE2 + 13,14,dihydro-15-keto-PGE2 metabolite), 
(c) LTB4, and (d) total cysLT levels were determined in BAL fl  uid obtained 
1 h after the last aerosol OVA challenge on day 23 (acute asthma model) 
from saline- and OVA-treated sPLA2-X+/+ (+/+) and sPLA2-X−/− (−/−) 
mice. Data represent the mean ± SEM. *, P < 0.05 versus other groups.874  GROUP X PHOSPHOLIPASE A2 AND AIRWAY INFLAMMATION | Henderson et al.
In OVA-treated wild-type mice, a strong signal in im-
munohistochemical detection of sPLA2-X in mouse lung 
sections was seen in airway epithelial cells and alveolar mac-
rophages. sPLA2-X colocalized with airway epithelial cells 
expressing mucin 5AC, a major gel-forming mucin of mouse 
(44) and human (45) airway epithelial cells. Studies using in 
situ hybridization for mRNA detection have shown that hu-
man lung epithelial cells also express sPLA2-X, along with 
sPLA2-V (24). It is generally thought that airway epithelial 
cells lack the lipoxygenases and cyclooxygenases needed to 
convert free arachidonate into leukotrienes and prostaglan-
dins. However, in vitro cell co-culture studies have shown 
that arachidonate released from stimulated airway epithelial 
cells can be transferred to nearby macrophages and eosino-
phils for oxygenation leading to eicosanoids (46, 47). Thus, a 
reasonable working hypothesis for the results seen in the cur-
rent study is that airway epithelial cell sPLA2-X generates free 
arachidonate, which is converted into proinfl  ammatory eico-
sanoids by nearby leukocytes. Studies are underway to test 
this hypothesis by selectively disrupting the sPLA2-X gene in 
airway epithelial cells.
Our data demonstrating a profound eff  ect of sPLA2-X 
defi  ciency on Th2 cell–driven airway infl  ammation and re-
modeling in a mouse model of human asthma bring a new 
dimension to the PLA2 fi  eld. These fi  ndings point to sPLA2-X 
as a potential target for the development of novel anti-
asthma drugs.
MATERIALS AND METHODS
Generation of the sPLA2-X–defi  cient  mouse. Embryonic stem cells 
(129SvEvBrd-derived) containing a mutated sPLA2-X gene were prepared by 
a high throughput gene trapping technique and used at Lexicon Genetics 
Inc. to generate a chimeric mouse in the 129SvEvBrd/C57BL/6J mixed 
background, as previously described (48, 49). This approach uses a multiplic-
ity of infection with virus that disfavors multiple insertions of the trapping 
cassette. The sPLA2-X−/− mouse was generated by breeding, and the geno-
type was verifi  ed by PCR using the primers LTR2, upper, and lower (primer 
sequences and PCR conditions are provided in Table S1, available at http://
www.jem.org/cgi/content/full/jem.20070029/DC1). LTR2 and lower 
give the mutant band of 320 bp, and upper and lower give the wild-type 
band of 392 bp. Two lines of evidence indicate that the trapping cassette is 
present as a single copy in the genome: (a) rapid amplifi  cation of cDNA ends 
sequencing on the 3′ fusion transcript revealed only a single sequence, and 
(b) quantitative PCR on the neomycin cassette demonstrated only a single 
copy in heterozygote mice.
Analysis of sPLA2-X mRNA and protein. We used primers to exons 
2 and 4 for PCR analysis of cDNA isolated from mouse tissues. Mouse 
testis was ground in RNA lysis buff  er (600 μl/100 mg of tissue; Promega) 
on ice, and RNA was isolated from 175 μl of suspension using a kit (Z3100; 
Promega). A 5-μl aliquot of the resultant 100 of RNA solution in water was 
converted to 20 μl of cDNA solution using a kit (Marligen Biosciences, 
Inc.). 1 μl of cDNA was used in a 25-μl PCR reaction with primers 
  directed at the mouse glyceraldehyde-3–phosphate dehydrogenase mRNA 
sequence and predicted to form a 500-bp product spanning more than 
one exon. From the results of agarose gel electrophoresis on 5 μl of the PCR 
product after 23, 27, and 31 cycles of PCR, the amount of cDNA required 
just to show a perceptible band at 500 bp after 23 cycles was estimated. This 
amount was used in a second PCR reaction with the primers sPLA2-X–F4 
(from exon 2) and sPLA2-X–RC (from exon 4). These primers gave an 
sPLA2-X band of the correct size (480 bp) on a 2% agarose gel after 27 cycles 
of PCR with cDNA derived from testis from a sPLA2-X+/+ mouse, whereas 
39 cycles of PCR were required to see this same band from the same amount 
of cDNA derived from testis from the sPLA2-X−/− mouse, corresponding to 
 1,000-fold reduction in sPLA2-X mRNA. No PCR band was seen in a 
blank control after 39 PCR cycles.
To examine sPLA2-X protein expression, stomachs from sPLA2-X−/− 
and sPLA2-X+/+ littermate mice were flash frozen in liquid nitrogen and 
lyophilized. Each stomach was soaked in 200 μl of saline, mixed by vortexing, 
and incubated at 4°C for 30 min. Samples were centrifuged at 16,000 g for 
10 min, and the supernatants were assayed for protein by the Bradford assay and 
for sPLA2-X using time-resolved immunoassay, as previously described (25).
Allergen challenge in mice. All animal use procedures were approved by 
the University of Washington Animal Care Committee. sPLA2-X−/− 
C57BL/129 mice and their wild-type sPLA2-X+/+ littermates received i.p. 
injections of 100 μg OVA (0.2 ml of 0.5 mg/ml; Pierce Chemical Co.) 
complexed with aluminum potassium sulfate (alum; Sigma-Aldrich) on 
days 0 and 14. Mice were anesthetized i.p. with 130 mg/kg ketamine and 
8.8 mg/kg xylazine in normal saline before receiving an i.n. dose of 100 μg 
OVA (0.05 ml of 2 mg/ml) on day 14, and 50 μg OVA (0.05 ml of 1 mg/
ml) on days 26, 27, and 28 (acute asthma model) or days 26, 27, 28, 47, 61, 
73, 74, and 75 (chronic asthma model). Control groups received 0.2 ml of 
normal saline with alum i.p. on days 0 and 14, and 0.05 ml of saline with-
out alum i.n. on days 14, 26, 27, and 28 or days 14, 26, 27, 28, 47, 61, 73, 
74, and 75. Mouse plasma samples were obtained on day 29 from the 
OVA- and saline-treated groups and assayed for OVA-specifi  c IgE (50). 
For eicosanoid analysis studies, mice were immunized i.p. with 10 μg 
OVA and 1.125 mg alum in 0.2 ml of normal saline on days 0, 7, and 14 
and exposed to 1% aerosolized OVA, as previously described by Myou 
et al. (51) for 40 min on days 21, 22, and 23. Control groups received 0.2 ml 
of normal saline with alum i.p. on days 0, 7, and 14, and saline by aerosol 
on days 21, 22, and 23.
Pulmonary function testing. On day 29, invasive pulmonary mechanics 
were measured in mice in response to methacholine in the same manner as 
previously described (3), with the following modifi  cations: (a) the thorax 
was not opened; (b) mice were ventilated with a tidal volume of 200 μl and 
a respiratory rate of 120 breaths per minute using a MiniVent Ventilator 
for Mice (Harvard Apparatus); (c) mice received aerosolized solutions of 
methacholine (0, 3.125, 6.25, 12.5, 25, and 50 mg/ml in normal saline) via 
a nebulizer aerosol system (AER 1021; Buxco Electronics) with a 2.5–4-μm 
aerosol particle size generated by a nebulizer head (NEB0126; Nektar 
Therapeutics); and (d) a commercial plethysmography system consisting 
of a plethysmograph (model PLY4111), amplifi  er and pressure transducer 
system (MAX II), and Biosystem XA software (all obtained from Buxco 
Electronics)  was used to determine RL as calculated from the measures of 
pressure and fl  ow and expressed as cm H2O/ml/s. Noninvasive plethysmo-
graphy was also assessed on day 29, as described in Supplemental materials 
and methods (available at http://www.jem.org/cgi/content/full/jem
.20070029/DC1).
BAL. After tying off   the left lung at the mainstem bronchus, the right lung 
was lavaged three times with 0.5 ml of normal saline either 1 h (for eico-
sanoid assays) or 24 h (for cytokine assays) after the fi  nal OVA or saline treat-
ment. The BAL fl  uid was centrifuged at 250 g, and the supernatant was 
processed for eicosanoid assays, as described in detail in Supplemental materials 
and methods. Total BAL fl  uid cells were counted with eosinophils stained 
with 0.05% eosin (3), and the number of CD3+, CD4+, and CD8+ 
T cells was determined by cytofl  uorimetry. On day 29, alveolar macrophages 
were isolated from the BAL fl  uid cells by adherence to Esco Fluro slides 
(Erie Scientifi  c Company) for 2 h in RPMI 1640 with l-glutamate (Cellgro; 
Mediatech, Inc.) in humidifi  ed 5% CO2/95% air at 37°C, as previously de-
scribed (52). To remove nonadherent cells, the slides were washed six times 
in PBS, and adherent cells were stained for sPLA2-X expression.JEM VOL. 204, April 16, 2007  875
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Cytofl  uorimetry. BAL fl  uid cells were preincubated with 1 μg Fc Block 
(anti–mouse CD16/CD32 [FcγIII/II receptor]; BD Biosciences) per 106 
cells in 50 μl of staining buff  er (BD Biosciences) for 15 min at 4°C to reduce 
nonspecifi  c immunostaining. After washing in PBS containing 1% FBS, 
pH 7.4 (Sigma-Aldrich),  106 cells were incubated with 50 μl PBS + 1% FBS 
buff  er containing 1 μg each of the following antibodies purchased from BD 
Biosciences: PE–anti–mouse CD3e (CD3ε chain; 145-2C11), allophycocy-
anin –anti–mouse CD4 (L3T4; RM4-5), and FITC–anti–mouse CD8a 
(Ly-2; 53-6.7) for 20 min at 4°C. Cells were fi  xed in 1% paraformaldehyde 
in PBS for 16 h at 4°C, and cytofl  uorimetry was performed with a fl  ow 
cytometry system (Cytomics FC500; Beckman Coulter).
RT-PCR. Total RNA was isolated from the right lung using an RNeasy 
mini kit (QIAGEN), and mRNA levels for IL-1β, IL-2, IL-4, IL-5, IL-12α 
(IL-12 p35 subunit), IL-12β (IL-12 p40 subunit), IL-13, IFN-γ, and 
GAPDH were determined by RT-PCR. A PCR System (7900HT Fast 
Real-Time; Applied Biosystems) was used, and SYBR green PCR master 
mix was used (Applied Biosystems. 0.2 μg RNA was used to synthesize fi  rst-
strand cDNA with the fi  rst-strand synthesis system (SuperScript III; Invitro-
gen). All primers were designed using primer 3 and crossed large expanses of 
the intronic sequence (Table S1). PCR sizes were  100 bp and were con-
fi  rmed by gel electrophoresis. RT-PCR readings had to be within the range 
of the standard curve. Sample cDNAs were diluted to 20 ng/μl.
Lung and spleen histopathology. The trachea, upper and lower lobes of 
the left lung, and spleen were fi  xed for 24 h in 10% neutral buff  ered formalin 
solution. The tissues were embedded in paraffi   n and cut into 5-μm sections. 
For lung morphometry, 10 airways (0.4–0.7 mm in diameter and sur-
rounded by smooth muscle cells) per mouse were randomly selected and ex-
amined by individuals blinded to the protocol design (3). The sections were 
stained with hematoxylin and eosin to evaluate airway edema (i.e., alve-
olar fl  ooding by amorphous material) on a semiquantitative 0–4+ scale 
(0 = 0–10% alveoli with edema; 1 = 10–20% alveoli with edema; 2 = 20–30% 
alveoli with edema; 3 = 30–40% alveoli with edema; and 4 = 40–50% 
alveoli with edema) (50) and total infl  ammatory cell infi  ltration (3) on a 
semiquantitative scale ranging from 0–4+ and eosinophil numbers per unit 
of lung tissue area (2,200 μm2). Each fi  eld, at magnifi  cation of 400 using a 
micrometer disc (Whipple; Bausch & Lomb), represented 2,200 μm2 of tis-
sue area. The smooth muscle mass of the smooth muscle cell layer beneath 
the airway epithelial cell basement membrane was assessed on a 0–4+ scale 
at three sites tangential to each airway cross-section examined (4). The sec-
tions were stained with alcian blue/periodic acid Schiff   (PAS) reaction to 
identify airway goblet cells and mucus (3). The number of goblet cells was 
determined as the percentage of total airway epithelial cells in each airway 
examined. Mucus occlusion of the airway diameter was assessed on a 0–4+ 
scale. Each airway section was assigned a score for airway diameter occlusion 
by mucus based on the following criteria: 0 = 0–10% occlusion; 1 = 10–30% 
occlusion; 2 = 30–60% occlusion; 3 = 60–90% occlusion; and 4 = 90–100% 
occlusion (3). To determine subepithelial collagen deposition/fi  brosis in the 
airways, the sections were stained with Masson’s trichrome stain (4). The in-
tensity of the collagen deposition (0–4+ scale) was assessed in the immediate 
region beneath the epithelium containing the contractile elements and extra-
cellular matrix associated with the airways, as described by Leigh et al. (53)
Immunocytochemistry. sPLA2-X expression in mouse lung and spleen 
was localized by immunocytochemistry using light microscopy (54). Tissues 
were fi  xed in methyl Carnoy’s solution and embedded in paraffi   n, and 5-μm 
sections were cut, placed on slides (Super Frost Plus; VWR Scientifi  c), depar-
affi   nized, hydrated, and rinsed in PBS. All immunolabeling procedures were 
performed at 24°C. Endogenous peroxidase was inactivated by incubating the 
tissue sections in 0.75% hydrogen peroxide for 30 min. After rinsing in PBS, 
the sections were incubated with the primary antibody, polyclonal rabbit 
anti–sPLA2-X–specifi  c antisera (55), at a 1:50 dilution for 25 min, followed 
by rinsing in PBS and incubation with the secondary antibody, goat anti–
rabbit antibody conjugated to horseradish peroxidase (Vector Laboratories), at a 
1:20 dilution for 25 min. The controls were either PBS or normal rabbit IgG 
(Vector Laboratories) used in place of the primary antibody. After rinsing in 
PBS, the sections were incubated with 0.5% 3′,3′-diaminobenzidine tetra-
chloride (Sigma-Aldrich) in PBS and 0.15% hydrogen peroxide for 15 min 
for detection of peroxidase. The sections were rinsed in PBS, and nuclei 
were counterstained with 1% methyl green in distilled water for 3 min. The 
sections were dehydrated in ethanol, cleared in xylene, and mounted on glass 
slides with Permount (Fisher Scientifi  c). BAL fl  uid alveolar macrophages, 
isolated by overnight adherence to microscope slides, were also stained for 
sPLA2-X by immunocytochemistry.
Immunofl  uorescence confocal microscopy. For immunofl  uorescence 
double staining of mucin 5AC and sPLA2-X, lung tissue was frozen in liquid 
nitrogen immediately after collection, embedded in OCT compound (Tissue-
Tek; Sakura Finetek USA, Inc.), and cut into 10-μm-thick cryostat sections. 
After rinsing in PBS, the slides were fi  xed in acetone for 5 min, washed three 
times in PBS, and blocked in 2% dry milk for 30 min at room temperature. 
The sections were incubated with the primary antibodies (both at a dilution 
of 1:100 in PBS), rabbit anti–mouse sPLA2-X (55) and goat anti–mouse mucin 
5AC (K-20; Santa Cruz Biotechnology, Inc.), for 40 min at room tempera-
ture, washed three times in PBS, and incubated with the secondary antibod-
ies (both at a dilution of 1:100 in PBS; Invitrogen), Alexa Fluor 594 (i.e., red 
fl  uorophore) donkey anti–rabbit IgG and Alexa Fluor 488 (i.e., green fl  uo-
rophore) donkey anti–goat IgG, for 30 min at room temperature. After 
washing in PBS, coverslips were placed with IMMU-MOUNT (Shandon 
Inc.), and slides were stored in the dark at 4°C. Sections were examined on 
a confocal microscope (LSM510Meta; Carl Zeiss MicroImaging, Inc.) 
running software version 4.0. Fluorescence excitation was provided using an 
argon laser line (488 nm) and a helium–neon laser line (543 nm).
Cytokine and eicosanoid analyses. Lincoplex multiplexed biomarker 
immunoassays of BAL fl  uid for IL-1β, IL-2, IL-4, IL-5, IL-12 (p70), and 
IFN-γ were performed using Luminex instrumentation (3.2 pg/ml detec-
tion limit; LINCO Research) according to the manufacturer’s instructions. 
IL-13 (1.5 pg/ml detection limit; R&D Systems), LTB4 (13 pg/ml detec-
tion limit; Cayman Chemical), cysLTs (LTC4/LTD4/LTE4, 13 pg/ml de-
tection limit; Cayman Chemical), PGD2 (measured as the stable MOX 
derivative PGD2-MOX after treatment of the samples with methoxy-
lamine hydrochloride; 3.1 pg/ml detection limit using a PGD2-MOX en-
zyme immunoassay (EIA) kit; Cayman Chemical), and PGE2 (measured as 
the total of PGE2 [15 pg/ml detection limit using a PGE2 kit–monoclonal; 
Cayman Chemical] and its 13,14,dihydro-15-keto metabolite [2 pg/ml 
detection limit using a PGE2 metabolite EIA kit; Cayman Chemical]) were 
determined by EIA. The fraction of cysLTs that are LTC4, LTD4, and 
LTE4, was determined by combined liquid chromatography–electrospray 
tandem mass spectrometry using a modifi  cation of the method of Kita et al. 
(56). Full details of eicosanoid analyses are provided in Supplemental 
  materials and methods.
For fl   ow cytrometric analysis of intracellular cytokines, total splenic 
cell populations from experimental and control mice were plated in 24-
well plates (4 × 106 cells per well) and activated with 200 μg/ml OVA 
(Pierce Chemical Co.) overnight. The samples were stained with pericinin-
chlorophyll-a-protein–conjugated anti-CD4, allophycocyanin-conjugated 
anti-CD8, and PE-conjugated antibodies against the following cytokines: 
IL-4, IL-5, IL-10, TNF-α, and IFN-γ (antibodies were obtained from BD 
Biosciences and eBioscience). The intracellular staining for cytokines was 
performed using the manufacturer’s standard protocol (BD Biosciences). 
Samples were analyzed using a fl  ow cytometer (FACSCanto; BD Bio-
sciences), and the data were analyzed using FlowJo software (TreeStar Inc.).
For enzyme-linked IL-4 and IFN-γ immunospot (ELISPOT) assays (BD 
Biosciences), total spleen cells from OVA- and saline-treated sPLA2-X−/− 
mice and wild-type controls were collected, plated in 96-well plates (2 × 105 
cells/well), and incubated in triplicate in 5% CO2/95% air at 37°C in the ab-
sence or presence of 5 ng/ml PMA (Sigma-Aldrich) and 500 ng/ml ionomy-
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5 d according to the manufacturer’s protocol (BD Biosciences). CD4+ T cells 
were isolated from the spleen cells using Dynabeads Mouse CD4 (L3T4) and 
DETACHsBEAD Mouse CD4 (Dynal), according to the manufacturer’s in-
structions. 4 × 104 CD4+ T cells/well were incubated in triplicate in 5% 
CO2/95% air at 37°C in the absence or presence of 1 μg/ml of hamster anti–
mouse CD3ε/2 μg/ml of hamster anti–mouse CD28 monoclonal antibodies 
(BD Biosciences) for 5 d, and IL-4 immunospot was performed.
Statistical analysis. Data are reported as the mean ± SEM. Diff  erences 
were analyzed for signifi  cance (P < 0.05) by analysis of variance using the 
least signifi  cant diff  erence method.
Online supplemental material. Fig. S1 shows sPLA2-X expression in 
airway cells of OVA-treated sPLA2-X+/+ mice by immunocytochemistry. 
Fig. S2 shows that sPLA2-X expression is seen in splenic mononuclear cells 
in sPLA2-X+/+ mice but is absent in sPLA2-X−/− mice by immunocyto-
chemistry. Fig. S3 shows decreased goblet cell metaplasia and mucus re-
lease in the lungs of sPLA2-X−/− mice after allergen challenge in an acute 
asthma model. Fig. S4 shows reduced levels of eosinophils in BAL fl  uid 
of OVA-treated sPLA2-X−/− mice in a chronic asthma model. Fig. S5 
shows reduced allergen-induced airway infl  ammatory cell infi  ltration and 
edema in sPLA2-X−/− mice in a chronic asthma model. Table S1 provides 
the sequence of PCR primers and PCR conditions used. Supplemen-
tal materials and methods contains details of the procedure for BAL fl  uid 
eicosanoid analysis by liquid chromatography–electrospray tandem mass 
spectrometry and EIA and pulmonary function testing by noninvasive pleth-
ysmography. Online supplemental material is available at http://www.jem
.org/cgi/content/full/jem.20070029/DC1.
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